Moreover, HYD, a selective inhibitor of hepatic AOX1,33,34 was utilized to validate the therapeutic potential of AOX1 inhibition on NAFLD (Figure 3(e)). The gene discussed is AOX1; the disease is metabolic dysfunction-associated steatotic liver disease.